Gel enhances CAR T benefits in brains surgically treated for glioblastoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

According to researchers from the University of North Carolina Lineberger Comprehensive Cancer Center, pairing a newly developed gel with immunotherapy that was delivered to post-surgical mouse brains with glioblastoma improved the immunotherapy’s effectiveness.

These findings appeared Oct. 6, 2021 in Science Advances. 

In this mouse study, the CAR T-cell gel was placed to fill in the area where a glioblastoma tumor had just been surgically removed. Previous studies have shown that administering T cells alone produces limited benefit.

“We developed a gel made of fibrin, a protein most often associated with helping blood to clot. Applying a gel substance to an area of the brain to aid CAR T-cell therapy is unique in glioblastoma treatment,” Edikan Ogunnaike, a biomedical engineer at UNC and first author of the article, said in a statement. “The gel aided CAR T-cell distribution in the brain by acclimating the T cells to the post-surgical wound environment while also stopping the tumor from recurring.”

The researchers used concentrations of human fibrinogen, a protein produced by the liver, which was transformed to fibrin with enzymes to develop a porous gel that was mixed with CAR T cells and placed in the post-surgical brain area. 

The gel created web-like fibrin scaffolds in the brain, in which the CAR T cells uniformly enmeshed themselves into the pores of scaffolds. The scaffolds are biodegradable and do not cause inflammation, tissue death, or scarring.

Nine of 14 (64%) mice that received the gel and T cells were tumor free 94 days after treatment, compared to two of 10 (20%) mice who only received T cells. The researchers said if these findings can be replicated in human studies—they caution that many early laboratory findings don’t lead to clinical studies or new therapies—it would result in a great improvement in current treatment rates.

The investigators are currently looking at injecting CAR T cells to other parts of the brain. The process is being tested in pilot clinical studies to assess safety as well as to see if it elicits a greater distribution of CAR T cells.

“The gel might also allow for local delivery of other biological agents that could sustain T cell growth and counter suppression of an immunotherapy,” Ogunnaike said.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login